Neoepitope immunotherapy with APC targeting unit

A method for the treatment of a neoplasm, such as a malignant neoplasm or for inducing a therapeutic or ameliorating immune response against such neoplasm, in a mammalian patient, wherein the neoplasm exhibits epitopes, such as T-cell epitopes (neo-epitopes) that are not exhibited by non-neoplastic cells in the patient, the method comprising administering an immunogenically effective amount of a composition comprising

• A) an expression vector, which comprises a sequence of nucleotides encoding a fusion polypeptide, said fusion polypeptide comprising
• i) at least one antigenic unit, which comprises a sequence of amino acids of at least one neo-epitope of a patent's neoplastic cells;
• ii) at least one antigen presented cell (APC) targeting unit:
• iii) optionally a multimerization unit, such as a dimerization unit, which unit provides for the multimerization of said fusion polypeptide to comprise two or more antigenic units and two or more antigen presenting cell(APC) targeting units,
• wherein the APC targeting unit consists of or comprises a ligand selected from chemokine ligand 19 (CCL19) and chemokine ligand 21 (CCL21), or
• B) a system of at least two expression constructs comprising i) a first expression construct comprising a sequence of nucleotides encoding at least one antigenic unit, which antigenic unit comprises a sequence of amino acids of at least one neo-epitope of a patient's neoplastic cells, and iii a second expression construct comprising a sequence of nucleotides encoding at least one antigen presenting cell (APC) targeting unit,
• wherein the APC targeting unit consists of or comprises a ligand selected from chemokine ligand 19 (CCL19) and chemokine ligand 21 (CCL2 I),
• whereby somatic cells in the patient are brought to express the sequence of nucleotides contained within the expression vector;
• the method optionally further comprising administering a pharmaceutically acceptable carrier, diluent, or excipient.